Summary:
- Bristol-Myers Squibb (BMY, Financial) anticipates a significant year-over-year earnings boost.
- Analyst predictions show potential stock price upside for investors.
- Key earnings discussions will focus on guidance updates, tariff effects, and product developments.
Bristol-Myers Squibb (BMY) is poised to announce its first-quarter earnings results before the market opens on April 24. Analysts are expecting an impressive EPS of $1.50, reflecting a 134.1% increase from the previous year. However, anticipated revenues are projected to decrease by 9.1%, reaching $10.71 billion. Investors will be keenly observing updates regarding 2025 guidance, the repercussions of tariffs, the ongoing debate around drug pricing, and any new information concerning their emerging schizophrenia treatment, Cobenfy.
Wall Street Analysts' Forecast
According to projections from 22 Wall Street analysts, the average one-year target price for Bristol-Myers Squibb Co (BMY, Financial) is set at $57.25. This range includes a high estimate of $70.00 and a low estimate of $33.10. This average target suggests a potential upside of 19.72% from the current stock price of $47.82. For more in-depth projections, visit the Bristol-Myers Squibb Co (BMY) Forecast page.
The consensus recommendation from 28 brokerage firms places Bristol-Myers Squibb Co (BMY, Financial) at an average rating of 2.7, indicating a "Hold" status. The rating system is based on a scale from 1 to 5, where 1 indicates a Strong Buy and 5 suggests a Sell.
Using GuruFocus' proprietary metrics, the estimated GF Value for Bristol-Myers Squibb Co (BMY, Financial) in the coming year is $63.10. This represents an impressive upside of 31.95% from the current price of $47.82. The GF Value is an evaluation of the fair value at which the stock should be trading, calculated using historical multiples, historical business growth, and future performance estimates. For more comprehensive data, please visit the Bristol-Myers Squibb Co (BMY) Summary page.
